Stay updated on Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.

Latest updates to the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page
- Check4 days agoChange DetectedTaoyuan District, Taiwan, 333423 was updated to Taoyuan, Taiwan, 333423 in the locations list. The postal code remains 333423.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedStudy availability was updated by adding and removing certain clinical trial sites/locations, including changes to specific cities and administrative regions (e.g., in Chile, Finland, and Romania). The record also reflects an updated data-sharing detail setup around providing anonymized participant data under the study’s IPD plan.SummaryDifference0.8%

- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.5.0 added. Revision: v3.4.3 removed.SummaryDifference0.0%

- Check61 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3; no user-facing content changes are indicated.SummaryDifference0.0%

- Check89 days agoChange DetectedThe page shows a minor site maintenance update: addition of Revision: v3.4.2 and removal of the older funding-related note (Revision: v3.4.1); no changes to core study details, eligibility, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.